Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis

Doğan, Akif; ÖKSÜZ, Mustafa Ferhat; ORUÇOĞLU, NURDAN; TUFAN, Ayşe Nur; ERMURAT, Selime; COŞKUN, Belkıs Nihan; Dalkılıç, Ediz; PEHLİVAN, Yavuz

Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis

Belkıs Nihan COŞKUN, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Mustafa Ferhat ÖKSÜZ, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Selime ERMURAT, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Ayşe Nur TUFAN, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Nurdan ORUÇOĞLU, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Akif DOĞAN, (Uludağ Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Bursa, Türkiye)

Ediz DALKILIÇ, (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

Yavuz PEHLİVAN (Uludağ Üniversitesi, Tıp Fakültesi, Nefroloji ve Romatoloji Anabilim Dalı, Bursa, Türkiye)

European Journal of Rheumatology

3 1

Yıl: 2014 Cilt: 1 Sayı: 3 Sayfa Aralığı: 101 - 105 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis

Öz:

Amaç: Nötrofil lenfosit oranı (NLO) sistemik inflamatuvar hastalık takibi için değerli ve güvenilir bir yöntem olarak ortaya çıkmıştır. Biz burada inflamasyonun klinik takibinde NLO'nun rolünü değerlendirmeyi ve eritrosit sedimentasyon hızı (ESR), C-reaktif protein (CRP) ve Bath Ankilozan Spondilit Hastalık Aktivite İndeksi (BASDAI) gibi ölçümlerle NLO'nun ilişkisini karşılaştırmayı amaçladık. Materyal ve Metot: Çalışmaya 35 aktif ankilozan spondilit (AS) hastası ve 38 sağlıklı gönüllü dahil edildi. Hasta grubuna bir anti-tümör nekroz faktörü (TNF) ilacıyla tedavi edilecek hastalar alındı. Tam kan sayımı, ESR, CRP seviyesi ve BASDAI skoru tedavi öncesi ve tedaviden 3 ay sonra elde edildi. NRO, nötrofillerin lenfositlere oranı olarak matematiksel hesaplamayla belirlendi. Bulgular: Kontrol ve hasta gruplarının ortalama NLO değerleri sırasıyla 1.90±0.89 ve 2.67±1.17 idi (p<0.05). Hasta grubunun üç aylık tedavi sonrası 1.8±0.7 olan ortalama NLO değeri tedavi öncesi NLO değerinden anlamlı düşüktü (p<0.001). Tedavi sonrası ortalama ESR, CRP düzeyi ve BASDAI skoru başlangıç ortalama değerlerine göre anlamlı düşüktü (sırasıyla p<0.001, p=0.007, p<0.001). Ayrıca, NLO ile BASDAI, ESR ve CRP arasında korelasyon olduğu bulundu (sırasıyla r=0.388, p<0.001; r=0.455, p<0.0001 ve r=0.3389, p<0.005). Sonuç: Nötrofil lenfosit oranı AS hastaların takibinde güvenilir ve kolay erişilebilir bir yöntem olabilir.

Anahtar Kelime:

Konular: Romatoloji

Nötrofil lenfosit oranı ankilozan spondilit için anti-tümör nekroz faktörü (TNF) ilaçları başlamış hastalarda hastalık aktivitesinin belirlenmesinde değerli bir belirteç olabilir

Öz:

Objective: Neutrophil lymphocyte ratio (NLR) has emerged as a valuable and reliable method for follow-up of systemic inflammatory disease. We herein aimed to evaluate the role of NLR in the clinical follow-up of inflammation and also to compare its relationship with other measures, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Material and Methods: A total of 35 active ankylosing spondylitis (AS) and 38 healthy volunteers were included in the study. The patient group was enrolled for treatment with one anti-tumor necrosis factor (TNF) drug. Total blood count, ESR, CRP, and BASDAI score were obtained before and 3 months following the treatment. NLR was found with a mathematical calculation of the ratio of neutrophils with lymphocytes.Results: The mean NLR value of the control group and patients was 1.90±0.89 and 2.67±1.17, respectively (p<0.05). After a 3-month course of treatment, the patient group had a mean NLR value of 1.8±0.7, which was significantly lower than pretreatment values (p<0.001). The posttreatment mean ESR, CRP, and BASDAI scores were significantly lower than mean baseline scores (p<0.001, p=0.007, p<0.001, respectively). Also, NLR was found to be correlated with BASDAI, ESR, and CRP (r=0.388, p<0.001; r=0.455, p<0.0001; and r=0.3389, p<0.005, respectively).Conclusion: Neutrophil lymphocyte ratio could be a reliable and easily accessible method for follow-up of patients with AS

Anahtar Kelime:

Konular: Romatoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Gensler L. Clinical Features of Ankylosing Spon- dylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheuma- tology, 5th edition, Philadelphia, PA: USA; 2011. p. 1129-34. [CrossRef]
Reveille JD, Weisman MH. The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the Unit- ed States. Am J Med Sci 2013; 345: 431-6. [CrossRef]
Onen F, Akar S, Birlik M, Sari I, Khan MA, Gurler O, et al. Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey. J Rheumatol 2008; 35: 305-9.
Saxena A, Cronstein BN. Acute Phase Reactants and the Concept of Inflammation. In: Firestein GS et al, editors. Kelley's Textbook of Rheuma- tology, 9th edition. Philadelphia, PA: USA; 2013. p. 818-29. [CrossRef]
Dougados M, Gueguen A, Nakache JP, Velicitat P, Zeidler H, Veys E, et al. Clinical relevance of C-reactive protein in axial involvement of anky- losing spondylitis. J Rheumatol 1999; 26: 971-4.
Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. Rel- ative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26: 980-4.
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to de- fining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activitiy index. J Rheumatol 1994; 21: 2286-91.
Akkoc Y, Karatepe AG, Akar S, Kirazlı Y, Akkoc N. A Turkish version of the Bath Ankylosing Spon- dylitis Disease Activity Index: reliability and va- lidity. Rheumatol Int 2005; 25: 280-4. [CrossRef]
Braun J, Heijde van der D, Dougados M, Emery P, Khan MA, Sieper J, et al. Staging of patients with ankylosing spondylitis: a preliminary proposal. Ann Rheum Dis 2002; 61: 19-23.
Goie The HS, Steven MM, van der Linden SM, Cats A. Evaluation of diagnostic criteria for an- kylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in pa- tients with a positive clinical history screening test for ankylosing spondylitis. Br J Rheumatol 1985; 24: 242-9. [CrossRef]
Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol Suppl 1999; 57: 16-21.
Imtiaz F, Shafique K, Mirza SS, Ayoob Z, Vart P, Rao S. Neutrophil lymphocyte ratio as a mea- sure of systemic inflammation in prevalent chronic diseases in Asian population. Int Arch Med 2012; 5: 2. [CrossRef]
Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflam- mation-based neutrophil-lymphocyte ratio: ex- perience in patients with cancer. Crit Rev Oncol Hematol 2013; 88: 218-30. [CrossRef]
Berthelot JM, Tortellier L, Lavy-Bregeon D, Le Goff B, Maugars Y. High intraindividual week- to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNF alpha antagonist therapy for spondyloarthropathies? Joint Bone Spine 2008; 75: 167-71. [CrossRef]
de Vries MK, van Eijk IC, van der Horst-Bruinsma IE, Peters MJ, Nurmohamed MT, Dijkmans BA, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondyli- tis. Arthritis Rheum 2009; 61: 1484-90.
Jung SY, Park MC, Park YB, Lee SK. Serum am- yloid A as a useful indicator of disease activity in patients with ankylosing spondylitis. Yonsei Med J 2007; 48: 218-24. [CrossRef]
Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007; 74: 249-53. [CrossRef]
Yildirim K, Erdal A, Karatay S, Melikoglu MA, Ugur M, Senel K. Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med J 2004; 97: 350-3. [CrossRef]
Kaya H, Ertas F, Islamoglu Y, Kaya Z, Atilgan ZA, Cil H, et al. Association between Neutrophil to lymphocyte ratio and severity of coronary ar- tery disease. Clin Appl Thromb Hemost 2014; 20: 50-4. [CrossRef]
Kalay N, Dogdu O, Koc F, Yarlioglues M, Ardic I, Akpek M, et al. Hematologic parameters and angiographic progression of coronary athero- sclerosis. Angiology 2012; 63: 213-7. [CrossRef]
Akpek M, Kaya MG, Lam YY, Sahin O, Elcik D, Celik T, et al. Relation of neutrophil/lymphocyte ratio to coronary flow to in-hospital major ad- verse cardiac events in patients with ST-elevat- ed myocardial infarction undergoing primary coronary intervention. Am J Cardiol 2012; 110: 621-7. [CrossRef]
Tamhane UU, Aneja S, Montgomery D, Rogers EK, Eagle KA, Gurm HS. Association between admis-sion neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syn- drome. Am J Cardiol 2008; 102: 653-7. [CrossRef]
Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, et al. Utility of the neutrophil to lymphocyte ratio in predicting long- term outcomes in acute decompenısated heart failure. Am J Cardiol 2011; 107: 433-8. [CrossRef]
Azab B, Zaher M, Weiserbs KF, Torbey E, Lacossiere K, Gaddam S, et al. Usefulness of neutrophil to lym- phocyte ratio in predicting short- and long-term mortality after non-ST-elevation myocardial infarc- tion. Am J Cardiol 2010; 106: 470-6. [CrossRef]
Torun S, Tunc BD, Suvak B, Yildiz H, Tas A, Sayilir A, et al. Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol 2012; 36: 491-7. [CrossRef]
Celikbilek M, Dogan S, Ozbakır O, Zararsız G, Kücük H, Gürsoy S, et al. Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal 2013; 27: 72-6. [CrossRef]
Biyik M, Ucar R, Solak Y, Gungor G, Polat I, Gaipov A, et al. Blood neutrophil-to-lymphocyte ratio independently predicts survival in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2013; 25: 435-41.
Forget P, Machiels JP, Coulie PG, Berliere M, Pon- celet AJ, Tombal B, et al. Neutrophil: lympho- cyte ratio and intraoperative use of ketorolac or diclofenac are prognostic factors in different cohorts of patients undergoing breast, lung, and kidney cancer surgery. Ann Surg Oncol 2013; 20: 650-60. [CrossRef]
Lee DY, Hong SW, Chang YG, Lee WY, Lee B. Clin- ical significance of preoperative inflammatory parameters in gastric cancer patients. J Gastric Cancer 2013; 13: 111-6. [CrossRef]
Azab B, Jaglall N, Atallah JP, Lamet A, Raja-Surya V, Farah B, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancre- atitis. Pancreatology 2011; 11: 445-52. [CrossRef]
Markar SR, Karthikesalingam A, Falzon A, Kan Y. The diagnostic value of neutrophil: lymphocyte ratio in adults with suspected acute appendici- tis. Acta Chir Belg 2010; 110: 543-7.
Solak Y, Yilmaz MI, Sonmez A, Saglam M, Cakir E, Unal HU, et al. Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease. Clin Exp Nephrol 2013; 17: 532-40. [CrossRef]
Turkmen K, Guney I, Yerlikaya FH, Tonbul HZ. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal dis- ease patients. Ren Fail 2012; 34: 155-9. [CrossRef]
Ahsen A, Ulu MS, Yuksel S, Demir K, Uysal M, Erdogan M, et al. As a New Inflammatory Mark- er for familial Mediterranean fever: neutro- phil-to-lymphocyte Ratio. Inflammation 2013; 36: 1357-62. [CrossRef]
Öztürk ZA, Yesil Y, Kuyumcu ME, Bilici M, Öztürk N, Yeşil NK, et al. Inverse relationship between neutrophil lymphocyte ratio (NLR) and bone mineral density (BMD) in elderly people. Arch Gerontol Geriatr 2013; 57: 81-5. [CrossRef]
Gear AR, Camerini D. Platelet chemokines and chemokine receptors: Linking hemostasis, in- flammation, and host defense. Microcirculation 2003; 10: 335-50. [CrossRef]
Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. Journal of Thrombosis and Haemostasis 2003; 1: 1897-905. [CrossRef]
Martin JF, Shaw T, Heggie J, Penington DG. Mea- surement of the density of human platelets and its relationship to volume. Br J Haematol 1983; 54: 337-52. [CrossRef]
Soydinc S, Turkbeyler IH, Pehlivan Y, Soylu G, Gokte- pe MF, Bilici M, et al. Mean platelet volume seems to be a valuable marker in patients with Systemic Sclerosis. Inflammation 2014; 37: 100-6.
Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdo- gan A, Ozturk MA, et al. Mean platelet volume (MPV) as an inflammatory marker in ankylosing spondylitis and rheumatoid arthritis. Joint Bone Spine 2008; 75: 291-4. [CrossRef]

APA	COŞKUN B, ÖKSÜZ M, ERMURAT S, TUFAN A, ORUÇOĞLU N, Doğan A, Dalkılıç E, PEHLİVAN Y (2014). Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. , 101 - 105.
Chicago	COŞKUN Belkıs Nihan,ÖKSÜZ Mustafa Ferhat,ERMURAT Selime,TUFAN Ayşe Nur,ORUÇOĞLU NURDAN,Doğan Akif,Dalkılıç Ediz,PEHLİVAN Yavuz Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. (2014): 101 - 105.
MLA	COŞKUN Belkıs Nihan,ÖKSÜZ Mustafa Ferhat,ERMURAT Selime,TUFAN Ayşe Nur,ORUÇOĞLU NURDAN,Doğan Akif,Dalkılıç Ediz,PEHLİVAN Yavuz Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. , 2014, ss.101 - 105.
AMA	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. . 2014; 101 - 105.
Vancouver	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. . 2014; 101 - 105.
IEEE	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y "Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis." , ss.101 - 105, 2014.
ISNAD	COŞKUN, Belkıs Nihan vd. "Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis". (2014), 101-105.

APA	COŞKUN B, ÖKSÜZ M, ERMURAT S, TUFAN A, ORUÇOĞLU N, Doğan A, Dalkılıç E, PEHLİVAN Y (2014). Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. European Journal of Rheumatology, 1(3), 101 - 105.
Chicago	COŞKUN Belkıs Nihan,ÖKSÜZ Mustafa Ferhat,ERMURAT Selime,TUFAN Ayşe Nur,ORUÇOĞLU NURDAN,Doğan Akif,Dalkılıç Ediz,PEHLİVAN Yavuz Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. European Journal of Rheumatology 1, no.3 (2014): 101 - 105.
MLA	COŞKUN Belkıs Nihan,ÖKSÜZ Mustafa Ferhat,ERMURAT Selime,TUFAN Ayşe Nur,ORUÇOĞLU NURDAN,Doğan Akif,Dalkılıç Ediz,PEHLİVAN Yavuz Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. European Journal of Rheumatology, vol.1, no.3, 2014, ss.101 - 105.
AMA	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. European Journal of Rheumatology. 2014; 1(3): 101 - 105.
Vancouver	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis. European Journal of Rheumatology. 2014; 1(3): 101 - 105.
IEEE	COŞKUN B,ÖKSÜZ M,ERMURAT S,TUFAN A,ORUÇOĞLU N,Doğan A,Dalkılıç E,PEHLİVAN Y "Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis." European Journal of Rheumatology, 1, ss.101 - 105, 2014.
ISNAD	COŞKUN, Belkıs Nihan vd. "Neutrophil lymphocyte ratio can be a valuable marker in defining disease activity in patients who have started anti- tumor necrosis factor (TNF) drugs for ankylosing spondylitis". European Journal of Rheumatology 1/3 (2014), 101-105.